Transcenta Received Ind Clearance From Fda For Its Best-In-Class Masp2 Targeting Antibody Tst004 For The Treatment Of Iga Nephropathy
Transcenta Holding Limited A Clinical Stage Biopharmaceutical Company With Fully-Integrated Capabilities In Discovery, Research, Development And Manufacturing Of Antibody-Based Therapeutics, Announces That Tst004, Its Best-In-Class, Humanized Monoclonal Antibody Targeting Masp2, Has Received Ind Clearance From U.S. Food And Drug Administration (Fda).Masp2, Mannose-Binding Protein-Associated Serine Protease 2, Is A Key Enzyme In The Lectin Pathway Initiation Of Complement Activation. Studies Have Shown That Lectin Pathway Activation Contributes To Multiple Human Diseases Such As Immunoglobulin A Nephropathy (Igan), Hematopoietic Stem-Cell Transplantation
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!